Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Tiragolumab in Cancer of Unknown Primary
NCT06754501Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab and atezolizumab in cancer of unknown primary (CUP), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Rate and Adverse Events at 1 year. Started Apr 2025; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumab
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on NCT06754501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754501.